Endocrinology Vol. 139, No. 10 4353-4363
Copyright © 1998 by The Endocrine Society
Human Osteoclasts and Osteoclast-Like Cells Synthesize and Release High Basal and Inflammatory Stimulated Levels of the Potent Chemokine Interleukin-81
Linda Rothe,
Patricia Collin-Osdoby,
Yan Chen,
Teresa Sunyer,
Lala Chaudhary,
Alfie Tsay,
Steven Goldring,
Louis Avioli and
Philip Osdoby
Department of Biology (L.R., P.C.-O., Y.C., T.S., P.O.) and
Division of Bone and Mineral Research (P.C.-O., Y.C., L.C., L.A.,
P.O.), Washington University, St. Louis, Missouri 63130; and the
Department of Rheumatology (A.T., S.G.), Harvard Institutes of
Medicine, Boston, Massachusetts 02115
Address all correspondence and requests for reprints to: Dr. Philip Osdoby, Department of Biology, Box 1229, Washington University, St. Louis, Missouri 63130. E-mail: osdoby{at}biodec.wustl.edu
 |
Abstract
|
|---|
Chemokines, including interleukin-8 (IL-8), function as key mediators
in diverse inflammatory disorders via promoting the recruitment,
proliferation, and activation of vascular and immune cells. IL-8 levels
are elevated in inflammatory diseases, such as rheumatoid arthritis,
osteoarthritis, osteomyelitis, and periodontal disease, that also
exhibit progressive bone loss. Therefore, it is possible that IL-8
contributes to the osteopenia associated with these pathological
conditions. Although macrophages, neutrophils, and endothelial cells
are considered the primary sources of inflammation-induced IL-8
increases, we report here for the first time that human bone
marrow-derived osteoclast-like cells (hOCL) as well as authentic
bone-resorbing human osteoclasts (hOC) isolated from osteoporotic
femoral heads express messenger RNA (mRNA) for IL-8 and secrete high
levels of IL-8 during culture. Basal IL-8 release by cultured hOC or
hOCL was orders of magnitude greater than the release of the
proinflammatory cytokines IL-1ß, IL-6, and tumor necrosis factor-
.
At a cellular level, in situ hybridization analysis
revealed that IL-8 mRNA was expressed in resorbing hOC of rheumatoid
arthritic pannus and was substantially greater than that expressed in
hOC of noninflammatory giant cell tumor of bone tissue. Therefore, the
potential inflammation-mediated induction of IL-8 was directly assessed
using cultured hOCL. IL-8 release was stimulated by proinflammatory
signals (IL-1
, tumor necrosis factor-
, lipopolysaccharide, or
phorbol 12-myristate 13-acetate), unaffected by various other
osteotropic modulators (transforming growth factor-ß1 and -ß3,
IL-6, 17ß-estradiol, or calcitonin) and was decreased by
interferon-
, vitamin D3, and the antiinflammatory
glucocorticoid dexamethasone. Changes in IL-8 secretion were paralleled
by corresponding changes in IL-8 mRNA steady state levels. We conclude
that hOC and hOCL synthesize and secrete high constitutive and
inflammation-stimulated levels of the chemokine IL-8. Consequently,
hOC-derived IL-8 could act as an important regulatory signal for bone,
vascular, and immune cell recruitment and activation during normal and
pathological bone remodeling.
 |
Introduction
|
|---|
INTERLEUKIN-8 (IL-8) is the prototypical
member of a superfamily of small (810 kDa), inducible, secreted
chemoattractant cytokines (chemokines) that were originally discovered
as monocyte-derived factors capable of attracting and activating
neutrophils (1, 2, 3, 4). Many cell types are now known to synthesize and
release IL-8 (and other chemokines) in response to injury, infection,
inflammation, or various pathological conditions (2, 3, 4, 5). IL-8
production is induced by proinflammatory cytokines [IL-1, tumor
necrosis factor-
(TNF
), or granulocyte-macrophage
colony-stimulating factor] or other immune stimuli [bacterial
lipopolysaccharide (LPS), lectins, and protein kinase C activation].
The precursor protein (99 amino acids) undergoes cell type-dependent
sequential N-terminal proteolytic processing to yield products (6979
amino acids) of varying bioactivities (6). In addition to serving as a
potent chemoattractant activator of neutrophils, IL-8 exerts other
diverse proinflammatory or physiological effects on target cells,
including the stimulation of hematopoiesis, angiogenesis, mitogenesis,
bioactive lipid formation, protease activation, the release of
lysosomal enzymes, reactive oxygen species, cytokines, and nitric
oxide, and rapid changes in the expression or conformation of cell
surface adhesion proteins (e.g. ß-integrins and Mac-1),
F-actin, and cell shape (2, 3, 4, 5, 6, 7, 8, 9, 10, 11). Such biological actions are typically
mediated via elevated intracellular Ca2+ levels (12) that
occur following IL-8 ligand binding to specific cell surface receptors
that belong to the superfamily of seven-transmembrane spanning G
protein-coupled receptors (2, 3, 4, 5, 6, 7, 8, 9, 13). Consistent with its
proinflammatory actions in vitro, IL-8 levels are markedly
elevated in various inflammatory disorders, such as rheumatoid
arthritis, osteoarthritis, periodontal disease, psoriatic lesions,
pulmonary diseases, endotoxemia and sepsis, gastrointestinal
inflammation, and immune complex glomerulonephritis (2, 7, 8, 9). Whereas
ip or sc injections of IL-8 cause neutrophil migration, infiltration,
and activation at such sites (2, 7, 8, 9), neutralizing antibodies to IL-8
conversely suppress acute inflammatory reactions in various
inflammatory conditions (8, 14). These and many other studies have
shown IL-8 to be a major mediator involved in biological inflammatory
responses.
Bone loss is a typical hallmark of many inflammatory conditions and is
thought to be a consequence of both reduced osteoblast bone formation
and increased osteoclast (OC) bone resorption. Recently, we showed that
IL-8 (0.11.0 nM) directly inhibits osteoblast
characteristics important for their bone formative function (15, 16).
Therefore, a local rise in IL-8 levels could presumably contribute to
regional bone loss through suppressive effects on osteoblasts. At
higher concentrations (
10 nM), IL-8 also partially
inhibits the overall bone-resorptive activity of isolated rat and chick
OC; however, this appears to reflect IL-8-evoked increases in OC
motility to new sites of resorption rather than actual declines in the
resorptive capability of individual OC per se (15, 17, 18).
Formerly, human osteoblast-like cells (hOBL) were shown to also produce
this chemokine, the levels of which were elevated by inflammatory
cytokine stimulation and conversely suppressed by the antiinflammatory
glucocorticoid dexamethasone (19). However, aside from these initial
studies, little is known about the role of IL-8 in bone physiology,
specifically in relation to either osteoblast or OC development or
function. During the course of studies employing human OC-like cells
(hOCL), which exhibit most of the attributes of bone-resorptive OC
(20), we discovered that high levels of IL-8 were released into the
culture medium. This prompted us to ask whether human OC (hOC) might
also produce this potent intercellular signal molecule, a question that
had not been addressed before the current work. Over the past few
years, OC have been increasingly recognized as capable of producing a
variety of autocrine/paracrine-acting bone-active cytokines, free
radicals, matrix proteins, and other signal molecules. Thus, we
explored whether bone-resorbing hOC and related hOCL expressed
messenger RNA (mRNA) for IL-8, released measurable levels of this
chemokine, and exhibited altered IL-8 production in response to
inflammatory stimuli. Moreover, IL-8 mRNA expression levels in
resorbing hOC were assessed by in situ hybridization in
inflammatory and noninflammatory human bone tissues to learn whether
IL-8 levels were correlated with conditions of localized
osteopenia.
 |
Materials and Methods
|
|---|
hOC and hOCL
Authentic bone-resorptive hOC (
107) were isolated
from femoral heads discarded during hip replacement surgery on
osteoporotic patients or from segments of bone removed from sites of
implant loosening during resection (21). Briefly, the bone was cut into
small pieces and trypsin/collagenase treated with shaking, and the
released cells were enriched (to >40% and >80% on a per cell and a
per nuclear basis, respectively) for hOC by Percoll fractionation or
serum sedimentation. Highly purified (
90% on a per cell basis,
>98% on a per nuclear basis) hOC preparations were obtained by
immunomagnetic sorting using the specific anti-OC monoclonal antibody
(Mab) 121F (22). hOC preparations were cultured in OC medium [phenol
red-free medium 199 Earles salts with 8.3 mM
NaHCO3, 100 mM HEPES (pH 6.8), 5% FBS (Life
Technologies, Gaithersburg, MD), and 2.5% antibiotic/antimycotic] at
37 C in a 95% air-5% CO2 moist environment. The cells
expressed characteristic OC features: high tartrate-resistant acid
phosphatase activity, vitronectin receptor
(
Vß3 integrin), 121F Mab-reactive antigen,
mRNAs for calcitonin receptor, cathepsin K/O, and carbonic anhydrase
II, and resorption pit formation during culture on ivory or devitalized
bovine cortical bone slices (21). In vitro formed hOCL were
generated using bone marrow from discarded surgical specimens of human
rib bone, the mononuclear cells were Ficoll-Hypaque (Pharmacia,
Piscataway, NJ) separated, and the cells were resuspended in
MEM
(Life Technologies) with 10% FBS and 2% antibiotic/antimycotic for
culture at 40 x 106 cells/100-mm dish (21, 22). On
day 6, nonadherent cells were replated in medium with 10 nM
1,25-dihydroxyvitamin D3 and thereafter refed every 3 days
with medium containing 25% conditioned medium (CM) from UMR 106-01 OBL
to further OC-like differentiation (22, 23). After 23 weeks, stromal
cells were selectively removed by brief trypsinization, and hOCL were
detached to replate into 24-well dishes at 0.8 x 105
cells/well (21). After 48 h, hOCL were switched to phenol red-free
medium, modulators were given in fresh medium 12 days later, and CM
was collected, spun, and stored at -80 C. These multinucleated hOCL
express the key OC phenotypic features listed above for hOC, but form
few, if any, resorption pits in culture on ivory or bone slices (20, 21).
Human bone marrow stromal (hBMS) and hOBL cells
hBMS were obtained as the first adherent cell population of the
initial plating of human marrow mononuclear cells (above) based on the
report of Cheng et al. (24). Briefly, after removal of the
day 6 nonadherent cells, the adherent cells were cultured to
confluence, trypsin detached, and replated at 2 x 105
cells/100-mm dish (21). hBMS were refed before 48-h CM collection from
near-confluent cultures. For hOBL differentiation, 10-7
M dexamethasone was added to the proliferating hBMS (day 2)
and withdrawn (day 7) before collection of 48-h CM (24).
Modulator treatments
The following reagents were obtained from Sigma Chemical Co.
(St. Louis, MO): Escherichia coli LPS serotype 0111:B4
stored at 4 C as a 5 mg/ml stock in Hanks Balanced Salt Solution,
phorbol 12-myristate 13-acetate (PMA) stored at -80 C as a 8.1 x
10-4 M stock in ethanol, dexamethasone freshly
prepared as a 10-3 M stock in ethanol,
17ß-estradiol stored at -20 C as a 3.7 x 10-4
M stock in ethanol, and BSA fraction V (<0.1 ng/ml
endotoxin). 1,25-(OH)2D3, a gift from
Hoffmann-La Roche (Nutley, NJ), was stored dry at -80 C and
reconstituted at 10-3 M in ethanol before use.
Salmon calcitonin, also a gift from Hoffmann-La Roche, was stored as
10-3-M aliquots (4411 IU/mg) in acetate
solution at -80 C. Human recombinant cytokines [interferon-
(IFN
), IL-1
, IL-6, TNF
, transforming growth factor-ß1
(TGFß1), and TGFß3] were purchased from R&D Systems (Minneapolis,
MN), reconstituted in PBS with 0.1% low endotoxin BSA (and 4
mM HCl for TGFß stocks), and stored as aliquots at -80
C. Modulators were diluted in medium just before their administration
to cells, vehicle controls were tested in parallel, and CM was
collected after 24 h, spun, and stored at -80 C.
Quantification of cytokine release
Cytokine levels in CM were measured using specific enzyme-linked
immunoassay kits (R&D Systems) as recommended. Standard curves were run
with every assay. Each modulator was tested in three or more separate
culture wells per trial, and two to six independent trials were
performed per condition. Corresponding control medium for each trial
exhibited insignificant reactivity with each cytokine enzyme-linked
immunosorbent assay. Minimum detectable cytokine levels were 3.0 pg/ml
IL-8, 0.064 pg/ml IL-6, 0.1 pg/ml IL-1ß, and 0.11 pg/ml TNF
.
Results are expressed as nanograms of cytokine released per ml culture
medium or as nanograms of cytokine released per 106 cells.
Normalization to cell protein was performed using harvested cells in
the bicinchoninic acid protein assay (Pierce, Rockford, IL) with BSA as
a standard.
RNA isolation and RT-PCR
Total RNA was extracted using RNA STAT-60 (Tel-Test,
Friendswood, TX), first strand complementary DNA (cDNA) synthesized
using a cDNA cycle kit (Invitrogen, San Diego, CA), and PCR reactions
were performed using specific primer pairs from these locations: 1)
192212 and 338317 of GenBank locus HSMDNCF for the 147-bp IL-8
amplicon, 2) 340359 and 494475 from locus HUMACP5 for the 155-bp
tartrate-resistant acid phosphatase amplicon, 3) 409426 and 661642
from locus HUMCALREC for the 252-bp calcitonin receptor
amplicon, 4) 33253344 and 37643747 from locus HUMGAPDHG for the
221-bp glyceraldehyde-3-phosphate dehydrogenase amplicon, and 5)
749770 and 10931071 for the first round, and 800822 and
10931071 for the second round, from locus HUMERMCF for the 249-bp
estrogen receptor (ER) amplicon as previously described (25). PCR
products were separated in a 1.5% agarose gel and ethidium bromide
stained. All were of the expected size for the primers used, and
sequencing of select amplicon products, including IL-8 and estrogen
receptor, was performed to confirm their identity.
Northern blot analysis
Total RNA (2025 µg) was separated on denaturing 1%
agarose/formaldehyde gels (26), ethidium bromide stained to assess RNA
integrity/loading, transferred to nylon membranes (Schleicher and
Schuell), fixed by UV cross-linking (UV Stratalinker 2400, Stratagene,
La Jolla, CA), and prehybridized, and the blots were hybridized
overnight at 4245 C with a labeled 406-bp human IL-8 cDNA probe
(provided by Dr. S. Kunkel, Pathology, University of Michigan Medical
School, Ann Arbor, MI) (27) generated by random primer extension using
[32P]deoxy-CTP (New England Nuclear, Boston, MA) or by
digoxygenin-11-deoxy-UTP labeling (Genius, Boehringer Mannheim,
Indianapolis, IN). After hybridization with 106 cpm/ml
32P-labeled probe (see Fig. 7A
) or 10-10
M digoxygenin-11-deoxy-UTP-labeled probe (see Fig. 7B
),
specific signals were detected by autoradiography or chemiluminescence
on XAR-5 film (Eastman Kodak, Rochester, NY). Stripped blots were
rehybridized with a labeled cDNA probe for 18S RNA (provided by Dr. J.
Lian (26)) for normalization of IL-8 signals. Blots were quantified
(sum of the gray area) using a densitometer (Hewlett-Packard Scanjet,
Palo Alto, CA) linked to a Leica Quantimet image analysis system
(Leica, Deerfield, IL), and the results were expressed in arbitrary
densitometric units as relative ratios for IL-8/18S.

View larger version (42K):
[in this window]
[in a new window]
|
Figure 7. Steady state IL-8 mRNA levels are regulated in
hOCL by proinflammatory and antiinflammatory stimuli. A, hOCL were
cultured in the absence or presence of PMA (0.01 nM) or LPS
(0.5 µg/ml) for 8 h, after which RNA was extracted from the
cells, separated on agarose gels, and blotted to nylon membranes for
Northern analysis of IL-8 mRNA steady state levels. Subsequently, blots
were stripped and rehybridized with a probe to 18S ribosomal RNA to
normalize specific hybridization signals, and autoradiograms were
quantified by densitometric analysis as described in Materials
and Methods. Normalized data for ratios of IL-8 mRNA relative
to 18S ribosomal RNA are depicted graphically in arbitrary
densitometric units, and the corresponding gel profiles for IL-8 and
18S hybridizations are shown below the graph. B, hOCL
were cultured in triplicate wells with IL-1 (0.1 nM) or
LPS (10 ng/ml), with or without dexamethasone (10 nM), for
8 h before RNA was extracted from each well and subjected to
Northern analysis for IL-8 mRNA steady state levels and 18S
normalization of blots. Data are presented as the mean ±
SEM of IL-8 mRNA levels relative to 18S ribosomal RNA
levels for triplicate wells in comparison with the mean IL-8/18S ratio
determined for LPS-treated hOCL (set at 100%).
|
|
In situ hybridization of human bone tissue sections
Human bone tissue samples from giant cell tumors of bone or
individuals with rheumatoid arthritis were fixed in 4%
paraformaldehyde (PF) for 2 days, decalcified (
5 weeks) in 14% EDTA,
washed in graded ethanols, transferred to xylenes, and embedded in
paraffin, and thin sections (5 µm) were cut and dried onto
poly-L-lysine-coated slides (28, 29). Slides were
deparaffinized in xylenes, rehydrated in graded ethanols, rinsed (5 min
each in 0.85% NaCl and PBS), refixed (4% PF, 20 min), PBS washed,
proteinase K treated (20 µg/ml, 20 min), dipped in PBS (5 min) and
then in 4% PF (5 min), acetylated in 0.25% acetic anhydride/100
mM triethanolamine, washed (5 min each in PBS and 0.85%
NaCl), dehydrated in graded ethanols, and air-dried. Sense and
antisense riboprobes were prepared from linearized IL-8 cDNA vector
(above) by incubation with T7 or SP6 RNA polymerase and
[35S]UTP (New England Nuclear) in the presence of
unlabeled nucleotides, 10 mM dithiothreitol, and
ribonuclease (RNase) inhibitor (Promega, Madison, WI), and the probes
were purified using NucTrap push columns (Stratagene, La Jolla, CA).
Probes (5 x 104 cpm/µl) were diluted in
hybridization buffer [4 x SSC (standard saline citrate), 50%
formamide, 10 mM Tris-HCl (pH 7.5), 1 mM EDTA
(pH 8.0), 10% dextran sulfate, 1 x Denhardts solution, 0.5
mg/ml total yeast RNA, 50 µg/ml yeast transfer RNA, 100 µg/ml
denatured salmon sperm DNA, 100 mM dithiothreitol, 0.1%
SDS, and 0.1% sodium thiosulfate], 50 µl were added per slide, a
glass coverslip was placed on top, and the slides were incubated (55 C,
16 h), washed (four times, 5 min each time, 25 C, 2 x SSC-10
mM 2-mercaptoethanol-1 mM EDTA), and RNase A
treated (20 µg/ml, 30 min; Pharmacia Biotech, Piscataway, NJ). Washed
slides (three times, 5 min each time, 60 C, 0.1 x SSC) were
dehydrated in graded ammonium acetate-ethanol solutions, air-dried,
dipped in Kodak NTB-2 emulsion, drained, air-dried (1 h), and placed in
a light-proof container with dessicant at 4 C for 48 weeks. Slides
were developed in Kodak D-19 developer, fixed, and hematoxylin/eosin
counterstained. Controls included sense probes and RNase treatment of
tissue sections before hybridization.
Statistical analysis
Data are presented as the mean ± SEM of at
least three culture wells in each of two to six independent trials.
Differences between treatments were analyzed using one-factor ANOVA.
For simultaneous comparisons between multiple treatments, significant
differences were determined using the post-ANOVA Bonferroni test.
Differences were considered significant for P <
0.05.
 |
Results
|
|---|
High levels of IL-8 are released by hOC and hOCL in culture
During the course of studies designed to examine the possible
production of inflammatory cytokines by multinucleated hOCL formed and
differentiated in vitro from human bone marrow mononuclear
cells, we discovered that such cells released high levels (137
ng/106 cells or 22 ng/ml) of the proinflammatory chemokine
IL-8 into the CM (Table 1
). By
comparison, the same CM samples contained much lower basal release
levels of the three other key inflammatory cytokines, IL-6 (150-fold),
TNF
(1,000-fold), and IL-1ß (17,000-fold), on either a per cell or
a per ml basis in relation to IL-8 (Table 1
). Whether authentic
bone-resorptive hOC also released significant basal amounts of IL-8 was
analyzed using hOC that were isolated and partially purified in
quantity from human femoral head samples, and subsequently cultured for
24 h in vitro (Table 1
). Like hOCL, hOC exhibited high
levels of IL-8 release (197 ng/106 cells or 48 ng/ml) into
the CM, and hOC secretion of IL-8 exceeded the release of TNF
(by
750-fold), IL-6 (by 25- to 40-fold), and IL-1ß (by 200-fold).
Somewhat unexpected was the finding that IL-1ß release was
substantially greater (by
150-fold) in authentic hOC cultures than
in hOCL cultures (Table 1
); possibly this relates to having isolated
hOC from osteoporotic bone, whereas marrow cells were obtained from
normal human bone for hOCL formation. Otherwise, hOC and hOCL released
comparable amounts within the same order of magnitude of IL-8, IL-6,
and TNF
. In contrast to hOC and hOCL, basal IL-8 release by human
bone cell populations unrelated to the hematopoietic lineage, such as
hBMS and stromal-derived hOBL cells, was notably lower on both a
nanograms per ml and per cell basis (Table 2
). Although IL-8 release from
differentiated hOBL was 10-fold greater than that from hBMS
osteoprogenitor cells, such levels were still 10-fold below the high
constitutive levels of IL-8 released by hOC and hOCL. Consistent with
detecting IL-8 protein in the CM, IL-8 mRNA was present in both hOC and
hOCL based on RT-PCR analysis (Fig. 1
).
Therefore, both hOC and hOCL express IL-8 mRNA and release high levels
of IL-8 into the CM during their culture in vitro.

View larger version (61K):
[in this window]
[in a new window]
|
Figure 1. Human OC and OCL express IL-8 mRNA. RT-PCR
amplicons of the expected size (147 bp) were obtained using IL-8
primers and RNA prepared from highly purified, 121F immunomagnetically
isolated authentic bone-resorbing hOC or in vitro formed
hOCL as described in Materials and Methods. Products
were separated on agarose gels and stained with ethidium bromide.
Amplicon products excised from gels were used for nucleotide sequencing
to confirm that they corresponded to human IL-8 mRNA. Lane 1, Size
markers; lane 2, negative control; lane 3, PCR product from hOC; lane
4, PCR product from hOCL.
|
|
IL-8 expression is localized to hOC of human bone tissue and
elevated in rheumatoid arthritis
As other cells (e.g. macrophages and vascular
endothelial cells) are also known to produce IL-8, and the hOC
preparations do not represent pure cell populations, it was important
to establish whether IL-8 production was localized to hOC of bone.
Human bone tissue sections prepared from individuals with or without an
inflammatory bone disorder were probed by in situ
hybridization for IL-8 mRNA expression. Whereas a faint hybridization
signal indistinguishable from the control signal (Fig. 2A
) was seen for hOC in sections from a
noninflammatory sample such as human giant cell tumor of bone (Fig. 2
, B and C), a more pronounced and specific hybridization signal was
localized to hOC of rheumatoid arthritic bone that had been similarly
processed (Fig. 2
, E and G). Negligible hybridization signals were
obtained using control sense probes on parallel tissue sections from
either the rheumatoid arthritic (Fig. 2
, D and F) or giant cell tumor
of bone samples (Fig. 2A
), or if the sections were pretreated with
RNase before hybridization with the IL-8 antisense probe (not shown).
Therefore, the IL-8 antisense signal localization to individual
resorbing hOC of human bone tissue indicates that hOC synthesize mRNA
for IL-8 and, consequently, may contribute to or account for the
release of this potent proinflammatory factor in isolated hOC cultures.
Moreover, hOC IL-8 mRNA levels in vivo may be significantly
elevated in inflammatory bone disorders associated with osteopenia,
such as rheumatoid arthritis.

View larger version (120K):
[in this window]
[in a new window]
|
Figure 2. IL-8 mRNA expression detected in resorbing hOC by
in situ hybridization analysis of human bone tissues.
Sections of human bone tissue from patients diagnosed with giant cell
tumors of bone (AC) or rheumatoid arthritis (DH) were prepared,
subjected to in situ hybridization with a radiolabeled
sense or antisense probe for IL-8, autoradiographed, and counterstained
with hematoxylin and eosin as described in Materials and
Methods. A, Human giant cell tumor of bone section hybridized
with a sense probe to IL-8 as a control. Giant cells
(arrows) are negative for a hybridization signal.
Magnification, x428. B, Little IL-8 antisense hybridization signal,
indistinguishable from negative sense hybridization controls, is
detectable in multinucleated resorbing hOC (arrows) of
giant cell tumor of bone tissue. Magnification, x428. C, Higher
magnification of multinucleated hOC (arrow) in human
giant cell tumor of bone, demonstrating the low degree of hybridization
with IL-8 probe observed in this noninflammatory tissue. Magnification,
x685. D and F, Human rheumatoid arthritic pannus section hybridized
with a sense probe to IL-8 as a control. Multinucleated hOC
(arrows) evidence minimal hybridization signals.
Magnification, x385. E and G, Resorbing multinucleated hOC
(arrows) exhibit moderate to high hybridization signals
with the IL-8 antisense probe. Magnification, x550. Control
hybridization sections pretreated with RNase also yielded negligible
signals in each of these bone tissue types (not shown).
|
|
Inflammatory stimuli further increase the high levels of IL-8
released by hOCL
The in situ findings suggested that IL-8 mRNA
expression by hOC of bone may be up-regulated at sites of inflammation,
perhaps in response to locally elevated concentrations of
proinflammatory cytokines such as IL-1 and TNF
. Because hOCL express
multiple OC characteristics and release IL-8 at levels comparable to
hOC, and larger numbers of hOCL are more readily available and of
greater purity than isolated hOC, hOCL were employed in further studies
to investigate the potential regulation of IL-8 production in response
to inflammatory signals. The proinflammatory cytokines IL-1
and
TNF
each significantly and dose dependently raised the levels of
IL-8 released into the CM beyond the already high basal level exhibited
by hOCL (Fig. 3
, A and B), and such rises
were initially detectable as early as 6 h after stimulation (not
shown). Bacterial LPS generated a striking rise in the IL-8 release by
these cells (Fig. 3C
), as did the phorbol ester PMA, which directly
activates protein kinase C, an intracellular signal commonly triggered
by inflammatory stimuli (Fig. 3D
).
Noninflammatory cytokines and systemic hormones do not stimulate
hOCL IL-8 release
Unlike the proinflammatory cytokines IL-1
or TNF
, other
bone-active cytokines such as IL-6
(10-810-11 M), TGFß1
(10-810-12 M), or TGFß3
(10-810-12 M) did not stimulate
IL-8 release from hOCL (not shown), whereas IFN
(50, 100, or 200
U/ml) reduced constitutive IL-8 release from hOCL (by 60 ± 2%,
62 ± 3%, and 63 ± 4%, respectively; all P
< 0.005). Neither of the antiresorptive osteotropic hormones,
17ß-estradiol (10-610-10 M)
or calcitonin (10-6 to 10-10 M),
altered the basal level of IL-8 secretion from hOCL (not shown),
although mRNA for receptors of both of these hormones were present in
cultured hOCL (Fig. 4
). Small, but
significant, reductions in basal IL-8 release by hOCL occurred after
treatment with 10-610-8 M
1,25-(OH)2D3 (Fig. 5A
). However, a more marked and
dose-dependent suppression of basal IL-8 release by hOCL was achieved
in response to 10-9 or 10-8 M of
the antiinflammatory glucocorticoid dexamethasone (Table 3
), which was not further reduced at a
concentration of 10-7 M of this osteotropic
hormone (20 ± 4% of control; P < 0.001).

View larger version (72K):
[in this window]
[in a new window]
|
Figure 4. Human OCL mRNA expression of characteristic OC
markers. RT-PCR amplicons of the expected sizes were obtained using
specific primers and RNA prepared from in vitro formed
hOCL as described in Materials and Methods. Products
were separated on agarose gels and stained with ethidium bromide.
Amplicon products excised from gels were used for nucleotide sequencing
to confirm that they corresponded to expected products. Lanes 2 and 6,
Size markers; lane 1, estrogen receptor- (249 bp); lane 3,
glyceraldehyde-3-phosphate dehydrogenase (221 bp); lane 4,
tartrate-resistant acid phosphatase (155 bp); lane 5, calcitonin
receptor (252 bp). Similar results were obtained in at least two
independent trials for each marker.
|
|

View larger version (40K):
[in this window]
[in a new window]
|
Figure 5. Vitamin D3 inhibition of constitutive
and inflammation-stimulated IL-8 release from cultured hOCL. Cultures
of hOCL were treated with increasing concentrations of vitamin
D3 in the absence (A) or presence (B) of IL-1 (0.1
nM) for 24 h, after which the levels of IL-8 secreted
into the culture medium were quantified as described in
Materials and Methods. Data were obtained from at least
two independent trials, each performed in triplicate culture wells for
each condition. A, IL-8 release is presented as the mean ±
SEM nanograms of IL-8 released per ml/mg cell protein.
Significant differences from control cultures are indicated (*,
P < 0.05; ***, P < 0.005; and
****, P < 0.001). B, IL-8 release is presented as
a percentage of the IL-8 secreted by control cultures of hOCL (100% =
100 ± 3 ng IL-8 released/ml·mg cell protein). Significant
differences from control cultures (++++, P <
0.001) and significant differences from IL-1 -stimulated levels (*,
P < 0.05, **, P < 0.01, and
***, P < 0.005) are indicated.
|
|
Interdependent regulation of inflammatory cytokine release by
hOCL
In addition to the effects of IL-1
and TNF
on stimulating
IL-8 release from hOCL, IL-1
significantly and dose dependently
increased the hOCL release of both TNF
and IL-6 (Table
4), and TNF
dose dependently elevated
both IL-1ß and IL-6 release (Table 3
). However, just as IL-6
treatment of hOCL did not modify IL-8 release, neither did IL-6 alter
IL-1ß or TNF
release from hOCL (Table 3
). The antiinflammatory
glucocorticoid dexamethasone conversely reduced basal IL-8 release
concurrent with that of IL-1ß, IL-6, and TNF
(Table 3
). Calcitonin
(10-1010-6 M) and
17ß-estradiol (10-1010-6 M),
which had no effects on basal IL-8 production by hOCL, also did not
alter IL-1ß or IL-6 release by hOCL (not shown). Thus, complex
interdependent regulatory pathways govern the production of these
inflammatory-associated bone-active cytokines from hOCL, which might
generate autocrine feedback and amplification regulatory circuits.
Cytokine stimulated levels of IL-8 release from hOCL are inhibited
by 1,25-(OH)2D3 or by dexamethasone
As 1,25-(OH)2D3 (Fig. 5A
) and dexamethasone (Table 4) each reduced basal IL-8 release from
hOCL, their effects on stimulated IL-8 release were investigated.
IL-1
stimulated IL-8 release was decreased by cotreatment of hOCL
with 1,25-(OH)2D3, although
such IL-8 levels remained significantly raised over those of
unstimulated control cultures in the presence of as much as
10-7 M of this hormone (Fig. 5B
). The very
high levels of IL-8 release stimulated by either LPS (0.110 µg/ml)
or PMA (10-810-6 M) were not
reduced by cotreatment of hOCL with 10-8 M
1,25-(OH)2D3 (not shown).
Dexamethasone was more potent than
1,25-(OH)2D3 in diminishing
both basal (Fig. 6A
) and
IL-1
-stimulated (Fig. 6B
) IL-8 release. In addition, dexamethasone
potently and dose dependently decreased hOCL release of IL-8 stimulated
by either TNF
(Fig. 6C
) or LPS (Fig. 6D
). In each case,
10-7 M dexamethasone was sufficient to return
stimulated IL-8 release to levels indistinguishable from control
values. In contrast, IL-1
(10-10
M)-stimulated IL-8 release by hOCL was not altered by
cotreatment with calcitonin (10-8 M),
17ß-estradiol (10-8 M), TGFß1
(10-1010-8 M), or TGFß3
(10-1010-8 M; not shown).
Steady state IL-8 mRNA expression levels correlate with IL-8
cytokine release levels by hOCL in response to modulators
Consistent with the large increases in IL-8 cytokine release by
hOCL evoked by LPS or PMA, IL-8 mRNA steady state levels in hOCL were
also markedly increased more than 2.5-fold in response to these stimuli
(Fig. 7A
). Similarly, steady state IL-8
mRNA levels were elevated by IL-1
treatment of hOCL (Fig. 7B
).
Conversely, cotreatment with dexamethasone dramatically reduced, by 4-
to 6-fold, the elevated IL-8 steady state mRNA levels elicited by
either LPS or IL-1
(Fig. 7B
). Consistent with its reduction of basal
IL-8 release from hOCL (Table 4), dexamethasone also decreased (by
2-fold) the basal IL-8 mRNA steady state levels in hOCL (not shown).
These findings were confirmed and extended by RNase protection assays,
which also demonstrated that IL-8 mRNA levels were partially elevated
by 2 h, peaked within 48 h, and thereafter declined by 24 h
in response to IL-1 stimulation (not shown). Thus, the regulation of
IL-8 cytokine release by hOCL in response to LPS, PMA, IL-1
, and
dexamethasone is reflected in corresponding parallel changes in hOCL
steady state expression levels for IL-8 mRNA.
 |
Discussion
|
|---|
Recently, several studies have indicated that human OC may
constitutively express mRNA and protein for the inflammatory cytokines
IL-6, TNF
, and IL-1ß in vivo (30); that rabbit OC
contain mRNA encoding IL-1ß, IL-6, IL-8, and the chemokine epithelial
neutrophil activating peptide-78 (31); and that mouse OC express
mRNA for the chemokine macrophage inflammatory protein-1
(MIP-1
)
in vivo (32). This and other recent evidence suggest that OC
may function as both effector and target cells in local
autocrine/paracrine regulatory circuits that govern normal and
pathological bone remodeling. Here, we report on our detailed studies
of the expression, production, and regulation of the proinflammatory
chemokine IL-8, in relation to IL-1ß, TNF
, and IL-6, by isolated
authentic bone-resorptive hOC and closely related in vitro
formed bone marrow-derived hOCL. The findings have demonstrated for the
first time that hOC and hOCL express mRNA for IL-8 and secrete high
basal levels of this potent chemokine, which can be further increased
by inflammatory conditions or signals. Overall, the similar basal
levels (within 1.5- to 4-fold) of IL-8, TNF
, and IL-6 secreted by
cultured hOC and hOCL provide further evidence of the OC-like nature
that develops during the in vitro formation of hOCL (20, 22, 33). More importantly, compared with the relatively low basal levels of
IL-1ß, TNF
, and IL-6 produced by cultured hOC and hOCL, IL-8
release was orders of magnitude higher (on a per cell or a per ml
basis). In fact, the levels of IL-8 constitutively released by cultured
hOC (48 ng/ml; 6 nM) and hOCL (22 ng/ml; 2.75
nM) or released by cultured hOCL in response to
inflammatory stimulation by IL-1
or TNF
(elevated 2- to 4-fold to
511 nM) were similar to those reported for endothelial
cells (34, 35, 36) and activated neutrophils or macrophages (37, 38, 39), cells
that are considered primary effector cells for mediating physiological
and pathophysiological immune-related processes. Thus, IL-8 release by
hOC and hOCL was at concentrations known to be biologically effective
for physiological cell responses via either of the two known high
affinity cell surface IL-8 receptors (CXCR-1 and CXCR-2), each of which
exhibits Kd values ranging from 0.110 nM in
various cell types (40). Although it is possible that other cells
present in the hOC preparations may have contributed to the levels of
IL-8 release measured, we confirmed that IL-8 mRNA was expressed in
highly purified 121F Mab immunomagnetically isolated hOC preparations
as well as in highly purified hOCL cultures and showed by in
situ hybridization analysis that IL-8 mRNA expression was
localized to individual resorbing hOC of human bone tissue. Therefore,
hOC potentially represent an additional source of this potent
chemoattractant and activating factor in bone, and its regulated
release by hOC could exert important paracrine or autocrine modulatory
influences on cells within the bone microenvironment, affecting cell
recruitment, attachment, differentiation, and physiological
function.
Virtually all IL-8-producing cell types respond to inflammatory
mediators, especially IL-1
and TNF
, with increased IL-8 mRNA
expression and IL-8 production (2, 3, 4, 19, 27). Several transcriptional
regulatory elements in the promoter region of the human IL-8 gene,
including activating protein-1 (AP-1), AP-2, nuclear factor-
B,
nuclear factor-IL-6-C/EBP, hepatocyte nuclear factor-1 (HNF-1),
glucocorticoid response element, and IFN regulatory factor-1 sites,
mediate these responses (3). In hOCL, as in other cells, both IL-8 mRNA
levels and IL-8 release were raised by the inflammatory stimuli PMA,
LPS, IL-1
, and TNF
, and conversely decreased by the
antiinflammatory glucocorticoid dexamethasone. In contrast, IL-6 did
not promote hOCL release of IL-8, IL-1ß, or TNF
, consistent with
its general inability to induce such cytokines in a broad range of cell
types (41), although in one report IL-6 induced the chemokine monocyte
chemoattractant protein-1 in human and rat osteoblasts (42). Although
TGFß isoforms have variably had no effect on (2), augmented (43), or
inhibited (44) cytokine-stimulated IL-8 production in other cells, and
inhibited MIP-1
production by bone marrow macrophages (45), neither
TFGß1 nor TGFß3 altered either basal or IL-1
-induced IL-8
secretion by hOCL. Whereas 1,25-(OH)2D3
decreased both basal and IL-1
-stimulated IL-8 release by hOCL,
similar to its suppression of IL-8 production by monocytes,
keratinocytes, or fibroblasts (3), such inhibition in hOCL was only
weakly dose dependent and did not surpass a 30% decline in stimulated
IL-8 levels even at hormonal concentrations as high as
10-7 M, in contrast to the potent inhibitory
effects of dexamethasone. Finally, neither of the bone resorption
inhibitory hormones, calcitonin or 17ß-estradiol, directly influenced
either basal or IL-1
-stimulated IL-8 release from hOCL, although
hOCL expressed mRNA for each receptor and have responded in other ways
to calcitonin (46) and 17ß-estradiol (47). Estrogen also does not
affect basal or stimulated IL-8 release by hBMS, hOB, or human MG-63
osteosarcoma cells (19, 48, 49), although estrogen can inhibit
cytokine-induced MCP-1 production in fibroblasts (50). Thus, hOCL
production of IL-8 is predominantly regulated by inflammatory mediators
and not by other osteotropic factors or hormones. Recent work has also
suggested more complex temporal modes of regulating IL-8 production in
hOCL, such as via estrogen modulation of IL-1 receptor expression in
hOCL, which subsequently modifies IL-1-mediated induction of IL-8 mRNA
(47).
Evidence for the in vivo expression of IL-8 by resorbing hOC
and its regulation by inflammatory stimuli was obtained from in
situ hybridization studies of human bone tissues. Thus, IL-8 mRNA
levels were higher in the resorbing hOC of rheumatoid arthritic pannus
than in hOC of giant cell tumors of bone. Although both of these
conditions represent pathological states in which OC numbers are
dramatically increased over the low number usually observed in human
bone, inflammation is not considered a hallmark of giant cell tumors of
bone, whereas rheumatoid arthritis is an autoimmune disease
characterized by chronic joint inflammation that leads to a progressive
destruction of cartilage and bone tissue in the afflicted joint (30, 51, 52, 53). Preliminary in situ hybridization studies on human
osteonecrotic bone samples have similarly evidenced only low IL-8 mRNA
levels in the resorbing hOC of this noninflammatory tissue (15).
Therefore, hOC recruited into the developing pannus region in
rheumatoid arthritis may respond to local stimulatory signals
elaborated in this microenvironment by increasing their synthesis of
IL-8, which could then contribute to the maintenance and amplification
of the inflammatory response in this disorder. Chemokines, including
IL-8, play key roles in both the initiation and maintenance phases of
the evolutionary pathogenesis of rheumatoid arthritis by virtue of
their capacity to recruit and activate leukocyte populations (monocytes
and neutrophils) infiltrating the synovial space and joint tissue, to
stimulate synovial cell proliferation and pannus formation at the
juncture of the synovium lining the joint capsule with the cartilage
and bone, and to activate endothelial cells and promote
neovascularization, which further favors the delivery of immune cells
from the vascular compartment into the inflamed joint (51, 52, 53, 54). Pre-OC
are also likely to be recruited, whereupon their exposure to locally
high concentrations of inflammatory mediators may promote their
development and bone-resorptive activity. Whereas limiting chemokine
levels appear optimal for the recruitment and passage of blood cells
across the vascular endothelium into the inflamed tissue site, adhesion
and activation of cells once in this location typically require high
saturating concentrations of chemokines (55), such as those detected
(up to 220 ng/ml IL-8) in the synovial fluid and serum of rheumatoid
arthritic individuals (38) and shown here to be released by cultured
hOC and hOCL. Consequently, hOC may significantly contribute to such
IL-8 increases and thereby exert paracrine inflammatory or
immunoregulatory influences on other cells infiltrating or present
within the arthritic lesion.
Both stimulatory and suppressive factors are commonly coproduced during
inflammation, and their relative balance is thought to provide a
mechanism for the sensitive and rapid modulation of the inflammatory
response (38). Although IL-8 appears to inhibit overall bone resorption
by isolated avian (17) or rat (18) OC, this has been attributed at
least in the rat system to a decrease in the proportion of OC actively
resorbing bone due to an IL-8-stimulated increase in their motility,
rather than to a suppression of the actual bone-resorptive capacity of
individual OC. Therefore, it is also possible that hOC-derived IL-8
exerts important autocrine actions, similar to those seen in
neutrophils (30), which might enhance OC degradation of bone at
inflammatory sites. This is consistent with the elevated numbers of OC
and augmented bone resorption activity exhibited in rheumatoid
arthritis seen here and in other studies. One potential
resorption-stimulating mechanism might be via IL-8 triggering of OC
release of superoxides (56), reactive oxygen species involved in OC
bone resorption (57, 58). In addition, hOC-derived IL-8 might elicit
recruitment and activation of additional OC, because select chemokines,
including IL-8 (17, 18) and MIP-1
(59, 60), promote migration or
chemotaxis of avian, rat, or human OC (42, 47, 48, 59, 61, 62). In
conclusion, we have shown that isolated bone-resorptive hOC and
in vitro formed hOCL synthesize and secrete high levels of
the potent proinflammatory chemokine IL-8, that mRNA and cytokine
levels for IL-8 are further raised in hOCL in response to various
inflammatory stimuli, and that IL-8 mRNA expression is localized
in situ to resorbing hOC of human bone tissues, wherein it
is particularly evident in inflammatory rheumatoid arthritic pannus.
Therefore, hOC-derived IL-8 may serve as an important
autocrine/paracrine mediator of bone cell physiology and
immunoregulation involved in normal or pathological bone
remodeling.
 |
Acknowledgments
|
|---|
The authors are indebted to Drs. Curt Merkel and William Maloney
for supplying us with femoral head segments of human bone derived from
osteoporotic patients from which we could isolate numerous human
bone-resorptive osteoclasts. We also greatly appreciate the assistance
of Mr. Fred Anderson and Ms. Sheng Zhang in the preparation of human
osteoclasts and bone marrow-derived osteoclast-like cells; Mr. Leonard
Rifas, Ms. Aurora Fausto, and Ms. Linda Halstead in the preparation of
human bone marrow-derived stromal cells and osteoblast-like cells; and
Dr. Oscar Joost, Dr. Alan Dean, and Mr. Ivan Zeiss in performing the
Northern blot analysis of IL-8 mRNA steady state expression.
 |
Footnotes
|
|---|
1 This work was supported by NIH Grants AR-32087 and DE-06891 (to P.O.)
and DK-46773 (to S.G.), and a Mineral Metabolism Fellowship (to
Y.C.). 
Received January 27, 1998.
 |
References
|
|---|
-
Yoshimura T, Matsushima K, Tanaka S, Robinson A,
Appella E, Oppenheim J, Leonard E 1987 Purification of a human
monocyte-derived neutrophil chemotactic factor that has peptide
sequence similarity to other host defense cytokines. Proc Natl Acad Sci
USA 84:92339237[Abstract/Free Full Text]
-
Baggiolini M, Dewald B, Moser B 1994 Interleukin-8
and related chemotactic cytokinesCXC and CC chemokines. Adv Immunol 55:97179[Medline]
-
Ben-Baruch A, Michiel D, Oppenheim J 1995 Signals
and receptors involved in the recruitment of inflammatory cells. J
Biol Chem 270:1170311706[Free Full Text]
-
Sozzani S, Locati M, Allavena P, Van Damme J, Mantovani
A 1996 Chemokinesa superfamily of chemotactic cytokines. Int
J Clin Lab Res 26:6982[Medline]
-
Zwahlen R, Walz A, Rot A 1993 In vitro and in vivo
activity and pathophysiology of human interleukin-8 and related
peptides. Int Rev Exp Pathol 34B:2741
-
Hebert C, Luscinskas F, Kiely J, Luis E, Darbonne W,
Bennett G, Liu C, Obin M, Gimbrone M, Baker J 1990 Endothelial and
leukocyte forms of IL-8. Conversion by thrombin and interactions with
neutrophils. J Immunol 145:33033040
-
Oppenheim J, Zachariae C, Mukaida N, Matsushima K 1991 Properties of the novel proinflammatory supergene "intercrine
cytokine family. Annu Rev Immunol 9:617648[Medline]
-
Hebert C, Baker J 1993 Interleukin-8: a review.
Cancer Invest 11:743750[Medline]
-
Baggiolini M, Clark-Lewis I 1992 Interleukin-8, a
chemotactic and inflammatory cytokine. FEBS Lett 307:97101[CrossRef][Medline]
-
Sunyer T, Rothe L, Jiang X-S, Osdoby P, Collin-Osdoby
P 1996 Pro-inflammatory agents, IL-8 and IL-10 upregulate
inducible nitric oxide synthase expression and nitric oxide production
in avian osteoclast-like cells. J Cell Biochem 60:469483[CrossRef][Medline]
-
Streiter RM, Polverini PJ, Arenberg DA, Walz A,
Opdenakker G, Van Damme J, Kunkel SL 1995 Role of C-X-C chemokines
as regulators of angiogenesis in lung cancer. J Leukocyte Biol 57:752762[Abstract]
-
Walz A, Meloni F, Clark-Lewis I, von Tscharner V,
Baggiolini M 1991 [Ca2+]i changes and
respiratory burst in human neutrophils and monocytes induced by
NAP-1/interleukin-8, NAP-2, and gro/MGSA. J Leukocyte Biol 50:279286[Abstract]
-
Horuk R 1994 The interleukin-8 receptor family:
from chemokines to malaria. Immunol Today 15:169174[CrossRef][Medline]
-
Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N,
Matsushima K 1994 Essential involvement of interleukin-8 (IL-8) in
acute inflammation. J Leukocyte Biol 56:559564[Abstract]
-
Osdoby P, Tsay A, Rothe L, Collin-Osdoby P, Goldring
S 1997 IL-8 expression is elevated in human osteoclasts associated
with arthritic and Pagets disease as well as in human osteoclast-like
cells exposed to inflammatory cytokines. J Bone Miner Res [Suppl
1] 12:S439
-
Rothe L, Collin-Osdoby P, Osdoby P 1995 Human
osteoclast-like cell-derived IL-8 inhibits osteoblast alkaline
phosphatase activity and is upregulated by IL-1. J Bone Miner Res
[Suppl 1] 10:T303
-
Collin-Osdoby P, Kirsch D, Anderson F, Joost O, Dean A,
Osdoby P 1996 The chemokine IL-8 as an autocrine inhibitor of
osteoclast bone resorptive activity via IL-8 receptors expressed by
avian osteoclasts and human osteoclast-like cells. J Bone Miner
Res [Suppl 1] 11:S357
-
Fuller K, Owens J, Chambers T 1995 Macrophage
inflammatory protein-1
and IL-8 stimulate the motility but suppress
the resorption of isolated rat osteoclasts. J Immunol 154:60656072[Abstract]
-
Chaudhary L, Avioli L 1994 Dexamethasone regulates
IL-1ß and TNF-
-induced interleukin-8 production in human bone
marrow stromal and osteoblast-like cells. Calcif Tissue Int 55:1620[CrossRef][Medline]
-
Kurihara N, Civin C, Roodman GD 1991 Osteotropic
factor responsiveness of highly purified populations of early and late
precursors for human multinucleated cells expressing the osteoclast
phenotype. J Bone Miner Res 6:257261[Medline]
-
Osdoby P, Anderson F, Maloney W, Collin-Osdoby P
Isolation and cultivation of human osteoclasts and osteoclast-like
cells. In: Koller M, Palsson B (eds) Human Cell Culture. Kluwer,
Boston, vol 4, in press
-
Galvin R, Cullison J, Avioli L, Osdoby P 1994 Influence of osteoclasts and osteoclast-like cells on osteoblast
alkaline phosphatase activity and collagen synthesis. J Bone Miner
Res 9:11671178[Medline]
-
Collin-Osdoby P, Oursler M, Rothe L, Webber D, Anderson
F, Osdoby P 1995 Osteoclast 121F antigen expression during
osteoblast conditioned medium induction of osteoclast-like cells in
vitro: relationship to calcitonin responsiveness, tartrate resistant
acid phosphatase levels, and bone resorptive activity. J Bone
Miner Res 10:4558[Medline]
-
Cheng S-L, Yang J, Rifas L, Zhang S-F, Avioli L 1994 Differentiation of human bone marrow osteogenic stromal cells in
vitro: induction of the osteoblast phenotype by dexamethasone.
Endocrinology 134:277286[Abstract]
-
Arts J, Kuiper G, Janssen J, Gustafsson J, Lowik C, Pols
H, Van Leeuwen J 1997 Differential expression of estrogen
receptors
and ß mRNA during differentiation of human osteoblast
SV-HFO cells. Endocrinology 138:50675070[Abstract/Free Full Text]
-
Wilson G, Hollar B, Waterson J, Schmickel R 1978 Molecular analysis of cloned human 18S ribosomal DNA segments. Proc
Natl Acad Sci USA 75:53675371[Abstract/Free Full Text]
-
Chaudhary L, Avioli L 1996 Regulation of
interleukin-8 gene expression by interleukin-1ß, osteotropic
hormones, and protein kinase inhibitors in normal human bone marrow
stromal cells. J Biol Chem 271:1659116596[Abstract/Free Full Text]
-
Gorn A, Rudolph S, Flannery M, Morton C, Weremowicz S,
Wang J, Krane S, Goldring S 1995 Expression of two human skeletal
calcitonin receptor isoforms cloned from a giant cell tumor of bone.
J Clin Invest 95:26802691
-
Lee S, Goldring S, Lorenzo J 1995 Expression of the
calcitonin receptor in bone marrow cell cultures and in bone: a
specific marker of the differentiated osteoclast that is regulated by
calcitonin. Endocrinology 136:45724581[Abstract]
-
OKeefe R, Teot L, Singh D, Puzas J, Rosier R, Hicks
D 1997 Osteoclasts constitutively express regulators of bone
resorption: an immunohistochemical and in situ hybridization study. Lab
Invest 76:457465[Medline]
-
Kobori M, Ikeda Y, Nara H, Kumegawa M, Nojima H,
Kawashima H 1997 C-X-C chemokines, IL-8, and ENA-78 are potential
autocrine/paracrine factors for osteoclasts: identification by
subtractive cDNA cloning and RT-PCR at a single cell level. J Bone
Miner Res [Suppl 1] 12:S439
-
Rahimi P, Wang C, Stashenko P, Lww S, Lorenzo J, Graves
D 1995 Monocyte chemoattractant protein-1 expression and monocyte
recruitment in osseous inflammation in the mouse. Endocrinology 136:27522759[Abstract]
-
James I, Walsh S, Dodds R, Gowen M 1991 Production
and characterization of osteoclast-selective monoclonal antibodies that
distinguish between multinucleated cells derived from different human
tissues. J Histochem Cytochem 39:905914[Abstract]
-
Kaplanski G, Porat R, Aiura K, Erban J, Gelfand J,
Dinarello C 1993 Activated platelets induce endothelial secretion
of interleukin-8 in vitro via an interleukin-1-mediated event. Blood 81:24922495[Abstract/Free Full Text]
-
White J, Lee J 1993 Effect of protein kinase
inhibitors on IL-8/NAP-1 release from human umbilical vein endothelial
cells. Agents Actions 39:C73C76
-
Collin-Osdoby P, Rothe L, Osdoby P 1997 Regulated
production of bone-active cytokines from human microvascular
endothelial cells in response to calciotropic hormones or growth
factors. J Bone Miner Res [Suppl 1] 12:S434
(Abstract)
-
Alstaedt J, Kirchner H, Rink L 1996 Cytokine
production of neutrophils is limited to interleukin-8. Immunology 89:563568[CrossRef][Medline]
-
Kunkel S, Luckas N, Kasama T, Streiter R 1996 The
role of chemokines in inflammatory joint disease. J Leukocyte Biol 58:612
-
McMillan M, Huribal M, Cunningham M, Bala R, Pleban W,
DAiuto M 1996 Endothelin-1, interleukin-6, and interleukin-8
levels increase in patients with burns. J Burn Care Rehabil 17:384389[Medline]
-
Baggiolini M, Dewald B, Moser B 1997 Human
chemokines: an update. Annu Rev Immunol 15:675705[CrossRef][Medline]
-
Streiter R, Standiford T, Chensue S, Kasahara K, Kunkel
S 1991 Induction and regulation of interleukin-8 expression. Adv
Exp Med Biol 305:2330[Medline]
-
Zhu J, Valente A, Lorenzo J, Carnes D, Graves D 1994 Expression of monocyte chemoattractant protein 1 in human
osteoblastic cells stimulated by proinflammatory mediators. J Bone
Miner Res 9:11231130[Medline]
-
Kuppner M, McKillop-Smith S, Forrester J 1995 TGF-ß and IL-1ß act in synergy to enhance IL-6 and IL-8 mRNA levels
and IL-6 production by human retinal pigment epithelial cells.
Immunology 84:265271[Medline]
-
Smith W, Noack L, Khew-Goodall Y, Isenman S, Vadas M,
Gamble J 1996 Transforming growth factor-ß1 inhibits the
production of IL-8 and the transmigration of neutrophils through
activated endothelium. J Immunol 157:360368[Abstract]
-
Maltman J, Pragnall I, Graham G 1996 Specificity
and reciprocity in the interactions between TGF-ß and macrophage
inflammatory protein-1
. J Immunol 156:15661571[Abstract]
-
Kurihara N, Chenu C, Miller M, Civin C, Roodman
G 1990 Identification of committed mononuclear precursors for
osteoclast-like cells formed in long term human marrow cultures.
Endocrinology 107:11371143[Abstract]
-
Sunyer T, Lewis J, Osdoby P 1997 Estrogen decreases
the steady state levels of the IL-1 signaling receptor (type I) while
increasing those of the IL-1 decoy receptor (type II) mRNAs in human
osteoclast-like cells. J Bone Miner Res [Suppl 1]
12:S135
-
Chase A, Xie J, Graves D 1996 Expression of
chemokines by normal human osteoblasts. J Bone Miner Res [Suppl
1] 11:S169
-
Greenfield E, Blaha M 1996 PTH, TNF
, and 1,25-D3
induce distinct temporal patterns of cytokine expression by
osteoblasts. J Bone Miner Res [Suppl 1] 11:S166
-
Kovacs E, Faunce D, Ramer-Quinn D, Mott F, Dy P,
Frazier-Jessen M 1996 Estrogen regulation of JE/MCP-1 mRNA
expression in fibroblasts. J Leukocyte Biol 59:562568[Abstract]
-
Feldman M, Brennan F, Maini R 1996 Role of
cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397440[CrossRef][Medline]
-
Badolato R, Oppenheim J 1996 Role of cytokines,
acute-phase proteins, and chemokines in the progression of rheumatoid
arthritis. Semin Arthritis Rheum 26:526538[CrossRef][Medline]
-
Streiter R, Standiford T, Huffnagle G, Colletti L,
Lukacs N, Kunkel S 1996 "The good, the bad, and the ugly:" the
role of chemokines in models of human disease. J Immunol 156:35833586[Medline]
-
Nishiura H, Tanaka J, Takeya M, Tsukano M, Kambara T,
Imamura T 1996 IL-8/NAP is the major T-cell chemoattractant in
synovial tissues of rheumatoid arthritis. Clin Immunol Immunopathol 80:179184[CrossRef][Medline]
-
Bevilacqua M 1993 Endothelial-leukocyte adhesion
molecules. Annu Rev Immunol 11:767804[CrossRef][Medline]
-
Wright L, Collin-Osdoby P, Osdoby P 1997 Differential regulation of free radical production by resorptive
osteoclasts and related non-resorptive bone marrow-derived
multinucleated giant cells. J Bone Miner Res [Suppl 1]
12:S291 (Abstract)
-
Garrett I, Boyce B, Oreffo R, Bonewald L, Poser J, Mundy
G 1990 Oxygen-derived free radicals stimulate osteoclastic bone
resorption in rodent bone in vitro and in vivo. J Clin Invest 85:632639
-
Key L, Wolf W, Gundberg C, Ries W 1994 Superoxide
and bone resorption. Bone 15:431436[Medline]
-
Kukita T, Nomiyama H, Ohmoto Y, Kukita A, Shuto T,
Hotokebuchi T, Sugioka Y, Miura R, Iijima T 1997 Macrophage
inflammatory protein-1a (LD78) expressed in human bone marrow: its role
in regulation of hematopoiesis and osteoclast recruitment. Lab Invest 76:399406[Medline]
-
Votta B, James I, Eichman C, Lee-Rykaczewski E, White J,
Gowen M 1996 C-C chemokines which interact via the RANTES/MIP-1
receptor are chemotactic for human osteoclast precursors. J Bone
Miner Res [Suppl 1] 11:S285
-
Williams S, Jiang Y, Cochran D, Dorsam G, Graves D 1992 Regulated expression of monocyte chemoattractant protein-1 in
normal human osteoblastic cells. Am J Physiol 263:C194C199
-
Takeshita A, Hanazawa S, Amano S, Matumoto T, Kitano
S 1993 IL-1 induces expression of monocyte chemoattractant JE in
clonal mouse osteoblastic cell line MC3T3E1. J Immunol 150:15541562[Abstract]
This article has been cited by other articles:

|
 |

|
 |
 
J. Lorenzo, M. Horowitz, and Y. Choi
Osteoimmunology: Interactions of the Bone and Immune System
Endocr. Rev.,
June 1, 2008;
29(4):
403 - 440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yoneda, N. Ishimaru, R. Arakaki, M. Kobayashi, T. Izawa, K. Moriyama, and Y. Hayashi
Estrogen Deficiency Accelerates Murine Autoimmune Arthritis Associated with Receptor Activator of Nuclear Factor-{kappa}B Ligand-Mediated Osteoclastogenesis
Endocrinology,
May 1, 2004;
145(5):
2384 - 2391.
[Abstract]
[Full Text]
[PDF]
|
 |
|